This observational, multicentre, real-world study found that the linagliptin-basal insulin regimen was as effective and safe as the basal-bolus insulin regimen in non-critically ill medicine department inpatients with T2D who have mild to moderate hyperglycaemia and who are treated at home without injectable therapies. The gene discussed is INS; the disease is type 2 diabetes mellitus.